Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 14;10:6323. doi: 10.1038/s41598-020-62953-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Snol-A caused growth arrest that was mediated by upregulation of p21^WAF1. (A) Cell cycle profiles of Snol-A treated SKOV-3 (6 and 10 µM), Saos-2 and MDA-MB-231(10 & 20 µM) cells showing increase in S phase and growth arrest. Treatment with higher doses of Snol-A, 10 µM, in SKOV-3 and 20 µM in MDA-MB-231 cells showed increase in apoptotic population. Quantitation (% sub-population) in control and Snol-A treated cells is shown on the right. (B) Immunoblots showing an increase in p21^WAF1 and decrease in CDK2, Cyclin A, Cyclin D1 and CDK4 proteins expression levels; quantitation of their levels is shown on the right. (C) RT-PCR based mRNA expression analysis showing increased p21^WAF1 transcript level on Snol-A treatment; quantitation of its transcript level is shown on the right. (D) p21^WAF1 promoter-dependent luciferase activity showed significant increase in Snol-A treated SKOV-3 cells. (E) Immunostaining of Cyclin D1 and CDK2 showed dose dependent decrease in Snol-A treated cells; Quantitation is shown on the right.